The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BD | Combinations of oral blood glucose lowering drugs | |
| 5 | A10BD19 | Linagliptin and empagliflozin |
| Code | Title | |
|---|---|---|
| A10BD20 | Metformin and empagliflozin |
| Active Ingredient | Description | |
|---|---|---|
| Linagliptin and Empagliflozin |
Antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes. Linagliptin is an inhibitor of DPP-4 an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide). Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2. |
|
| Metformin and Empagliflozin |
Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), and metformin hydrochloride, a member of the biguanide class. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GLYXAMBI Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SYNJARDY Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
